WESTON, Fla., Dec. 21, 2011 (GLOBE NEWSWIRE) -- Stemlogix, LLC announced today that it has expanded the cellular products and services it offers to veterinarians and their patients. In addition to the company's current premier "in-clinic" adipose derived stem cell kits and system, the company will now provide disposable kits that will allow veterinarians to produce stem cell therapy from bone marrow aspirate using the same system. The Stemlogix system provides veterinarians the ability to produce stem cell therapy "in-house" or "stall-side" in a convenient, affordable, same-day procedure. Stemlogix will also offer culture expanded bone marrow and adipose stem cells. Veterinary patients will now have the option to bank their stem cells for future use as well.
Research has shown that these regenerative stem cell therapies have been effectively used to treat degenerative diseases and acute tissue injuries. Stem cell therapies derived from adipose tissue and bone marrow are both showing promise in studies. Stemlogix is providing veterinarians with the most regenerative medicine capability possible and they can decide which regenerative treatment to provide their patients based on the latest research and their experience. Every patient is unique and Stemlogix believes that their individual condition will dictate which stem cell therapy the veterinarian chooses to use. In some cases, such as in valuable racing horses, veterinarians may want to treat them with both bone marrow and adipose stem cell therapy at the same or different time points in order to stimulate the most healing possible. As another example of a possible treatment regimen, a horse that suffers a tendon or ligament injury can be treated immediately with adipose or bone marrow stem cell therapy and part of the tissue sample can be sent to the Stemlogix laboratory for stem cell expansion and another dose can be provided to the injured horse a couple weeks later. Stemlogix believes this may give the patient an even better chance for clinical improvement and hopes to further demonstrate this in studies. Stemlogix is the only company that will allow veterinarians to have this option for the patients using the same system and company.
"We are excited about these additional regenerative medicine product offerings and we believe that Stemlogix now offers the most versatile regenerative medicine system in all of veterinary medicine," said Jason Griffeth, Chief Operating Officer at Stemlogix. "This is important to veterinarians, especially during a tough economy, because they can now provide more therapies to their patients using the same system and eliminate the need to purchase additional capital equipment from another company. These new products and services help us accomplish our goal to provide Stemlogix veterinary customers with extraordinary regenerative medicine capability and provide them with multiple regenerative options to treat their patients conditions," he added further.
About Stemlogix, LLC
Stemlogix is an innovative veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the best possible stem cell therapy to dogs, cats and horses at the point-of-care. Stemlogix provides veterinarians with the ability to isolate regenerative stem cells from a patient's own fat tissue or bone marrow directly and produce platelet rich plasma therapy on-site within their own clinic or where a patient is located. Stemlogix is the first company to provide veterinarians with the ability to offer multiple cellular therapies using the same system. Regenerative stem cells have been shown in studies to be effective in treating animal's suffering from osteoarthritis, joint diseases, tendon injuries, heart disorders, among other conditions. Stemlogix has a highly experienced team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple indications, and more. For more information about veterinary regenerative medicine please visit www.stemlogix.com.